Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
IPO Year: 2005
Exchange: NYSE
Website: prestigebrands.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2024 | $90.00 | Buy → Neutral | Sidoti |
| 6/21/2024 | $65.00 → $93.00 | Neutral → Buy | DA Davidson |
| 11/17/2022 | $71.00 | Buy | Canaccord Genuity |
| 5/10/2022 | $65.00 → $70.00 | Hold → Buy | Jefferies |
| 5/9/2022 | $63.00 | Perform → Outperform | Oppenheimer |
| 3/11/2022 | $156.00 → $142.00 | Outperform | BMO Capital |
| 11/15/2021 | $61.00 → $63.00 | Neutral | DA Davidson |
| 11/5/2021 | $123.00 → $126.00 | Sector Perform | RBC Capital |
| 8/6/2021 | $107.00 → $123.00 | Sector Perform | RBC Capital |
| 8/6/2021 | $52.00 → $61.00 | Neutral | DA Davidson |
Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic
TARRYTOWN, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 third quarter earnings release on Thursday, February 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes p
Revenue of $283.8 Million in Q2, Ahead of OutlookDiluted EPS of $1.09 in Q2, Up 2% Versus Prior YearNet Cash Provided by Operating Activities of Approximately $125 Million in First Six Months, Up Approximately 13%; Reduced Debt by $75 Million and Repurchased $38 Million Shares Year-to-DateReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2024. "Our second quarter results exceeded our sales and earnings expectations thanks to the strength of our diverse portfolio of mark
TARRYTOWN, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 second quarter earnings release on Thursday, November 7, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes pr
Revenue of $267.1 Million in Q1, Ahead of Expectations, down 4.4% versus Prior YearEPS of $0.98 and Adjusted EPS of $0.90 in Q1 Compared to $1.06 in the Prior YearCash from Operations of $54.8 Million up 13.9% versus Prior Year; Reduced Debt by $35 Million and Repurchased $26 Million SharesReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter ended June 30, 2024. "We are pleased that our first quarter results exceeded our sales and earnings expectations. First quarter revenues were stronger than expected, primarily due
TARRYTOWN, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 first quarter earnings release on Thursday, August 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes pri
Revenue of $277.0 Million in Q4 and $1,125.4 Million in Fiscal 2024Solid Consumption Trends in Q4 Offset by Near-Term Supply Chain ConstraintsAchieved Leverage Ratio of 2.8x at Year-End, Below Long-Term TargetBoard of Directors Authorize New $300 Million Share Repurchase ProgramInitial Full-Year Fiscal 2025 Organic Revenue Growth and EPS Outlook of Approximately 1% and $4.40 to $4.46, respectively TARRYTOWN, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2024. "Our full-year fiscal 2024 delivered stable earnings and cash flow, enabled by our leading brand portfolio
TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 fourth quarter and year-end earnings release on Tuesday, May 14, 2024 after the market close. The Company will host a conference call to discuss the results the following morning, May 15th, at 8:30 a.m. ET. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate via phone, listeners calling from the U.S. and Canada may dial 800-715-9871 using the conference ID 4304270. A conference call replay will be available
Revenue of $282.7 Million in Q3, Up 2.6% Versus Prior YearDiluted EPS of $1.06 in Q3, Up 2.2% Versus Prior YearReduced Leverage Ratio to 2.9x at Quarter EndRaising Full-Year Fiscal 2024 Earnings Outlook to Approximately $4.33 TARRYTOWN, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2023. "We are pleased with our continued strong results that exceeded our revenue and earnings expectations for the quarter. Solid revenue growth of nearly 3% was driven by our leading portfolio of brands and continued investment in our marketing playbook. This translated int
TARRYTOWN, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 third quarter earnings release on Thursday, February 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes p
Revenue of $286.3 Million in Q2, Ahead of OutlookDiluted EPS of $1.07 in Q2, Up Over 5% Versus Prior YearReduced Leverage Ratio to 3.0x at Quarter EndReaffirming Full-Year Fiscal 2024 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2023. "Our second quarter results build on a strong first quarter performance thanks to our diverse and leading portfolio of brands and broad distribution. This stable top-line performance was amplified by our strong financial model and resulted in second quarter mid-single
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
ARS - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
DEF 14A - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
PRE 14A - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
10-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
TARRYTOWN, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 third quarter earnings release on Thursday, February 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes p
TARRYTOWN, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced that Chief Financial Officer Christine Sacco's responsibilities have been expanded to include the role of Chief Operating Officer, effective immediately. In this enhanced position as COO/CFO, Ms. Sacco will oversee the Company's supply chain, in addition to her existing responsibilities. Ms. Sacco will continue to report to Ron Lombardi, Chief Executive Officer of Prestige. "Chris' strategic leadership and deep understanding of our business has been instrumental in our growth and success over her 8 years as CFO," said Ron Lombardi. "This expanded CO
Revenue of $283.8 Million in Q2, Ahead of OutlookDiluted EPS of $1.09 in Q2, Up 2% Versus Prior YearNet Cash Provided by Operating Activities of Approximately $125 Million in First Six Months, Up Approximately 13%; Reduced Debt by $75 Million and Repurchased $38 Million Shares Year-to-DateReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2024. "Our second quarter results exceeded our sales and earnings expectations thanks to the strength of our diverse portfolio of mark
TARRYTOWN, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 second quarter earnings release on Thursday, November 7, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes pr
TARRYTOWN, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 5, 2024 at 2:15 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the "Investors" section and the "Events and Presentations" tab, or by using the following link: https://ir.prestigebrands.com/events-presentations/events For those unable to participate during the live webcast, a replay option will be available on the Company's website following the event. About Prestige Consumer Healthcare Inc. Prestige Consumer Healthcar
Revenue of $267.1 Million in Q1, Ahead of Expectations, down 4.4% versus Prior YearEPS of $0.98 and Adjusted EPS of $0.90 in Q1 Compared to $1.06 in the Prior YearCash from Operations of $54.8 Million up 13.9% versus Prior Year; Reduced Debt by $35 Million and Repurchased $26 Million SharesReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter ended June 30, 2024. "We are pleased that our first quarter results exceeded our sales and earnings expectations. First quarter revenues were stronger than expected, primarily due
TARRYTOWN, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 first quarter earnings release on Thursday, August 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes pri
TARRYTOWN, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on Monday, June 10, 2024 at 1:30 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the "Investors" section and the "Events and Presentations" tab, or by using the following link: https://ir.prestigebrands.com/events-presentations/events For those unable to participate during the live webcast, a replay option will be available on the Company's website following the event. About Prestige Consumer Healthcare Inc.Prestige Consumer He
Revenue of $277.0 Million in Q4 and $1,125.4 Million in Fiscal 2024Solid Consumption Trends in Q4 Offset by Near-Term Supply Chain ConstraintsAchieved Leverage Ratio of 2.8x at Year-End, Below Long-Term TargetBoard of Directors Authorize New $300 Million Share Repurchase ProgramInitial Full-Year Fiscal 2025 Organic Revenue Growth and EPS Outlook of Approximately 1% and $4.40 to $4.46, respectively TARRYTOWN, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2024. "Our full-year fiscal 2024 delivered stable earnings and cash flow, enabled by our leading brand portfolio
TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 fourth quarter and year-end earnings release on Tuesday, May 14, 2024 after the market close. The Company will host a conference call to discuss the results the following morning, May 15th, at 8:30 a.m. ET. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate via phone, listeners calling from the U.S. and Canada may dial 800-715-9871 using the conference ID 4304270. A conference call replay will be available
SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00
DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously
Canaccord Genuity initiated coverage of Prestige Consumer with a rating of Buy and set a new price target of $71.00
Jefferies upgraded Prestige Consumer from Hold to Buy and set a new price target of $70.00 from $65.00 previously
Oppenheimer upgraded Prestige Consumer from Perform to Outperform and set a new price target of $63.00
BMO Capital reiterated coverage of Premium Brands Holdings with a rating of Outperform and set a new price target of $142.00 from $156.00 previously
DA Davidson reiterated coverage of Prestige Consumer with a rating of Neutral and set a new price target of $63.00 from $61.00 previously
RBC Capital reiterated coverage of Premium Brands Holdings with a rating of Sector Perform and set a new price target of $126.00 from $123.00 previously
RBC Capital reiterated coverage of Premium Brands Holdings with a rating of Sector Perform and set a new price target of $123.00 from $107.00 previously
DA Davidson reiterated coverage of Prestige Consumer with a rating of Neutral and set a new price target of $61.00 from $52.00 previously